December 3, 2024 – Santersus AG presented its groundbreaking NucleoCapture technology at the prestigious BRAIN Conference 2024 in London. The event brought together global experts to advance neurovascular research and discuss cutting-edge developments in brain health.
Elevated cfDNA levels are associated with brain injuries and disorders, making it a potential biomarker for diagnosing and monitoring conditions like traumatic brain injury (TBI), stroke, multiple sclerosis, and Alzheimer’s. Together, NETs and cfDNA contribute to blood-brain barrier disruption and neuroinflammation, exacerbating the progression of these and other neurological diseases.
Representing Santersus AG, Dr. Andrew Aswani, Chief Medical Officer, delivered a presentation on how the selective removal of NETs and cell-free DNA from the blood using NucleoCapture offers a transformative treatment approach for brain injuries, disorders and other neurological diseases.
Santersus AG’s participation at the conference reflects its commitment to driving innovation in brain health and advancing research into diseases influenced by immune and inflammatory responses.
About the BRAIN Conference
The BRAIN Conference is a leading international event dedicated to neurovascular research. The 2024 edition, held in London, focused on advancements in stroke, aneurysm management, and emerging technologies driving progress in brain health.